Gilead Sciences (NASDAQ:GILD) traded higher in the morning hours Thursday after announcing that a Phase 3 trial for its experimental therapy lenacapavir succeeded when used as a twice-yearly option to ...

Gilead Sciences (NASDAQ:GILD) announced on Tuesday that the European Commission granted marketing authorization for its antiviral therapy lenacapavir as a twice-yearly option for the prevention of HIV ...

Its smell was sickening passengers and crew. And a therapy-companion duck named Daniel Stinkerbutt who’d been paired up with a PTSD-pal waddled to his seat on a short intra-state flight and, ...

Gilead Sciences (NASDAQ:GILD) on Wednesday announced a collaboration with the Swiss non-profit The Global Fund to accelerate access to lenacapavir, its newly approved HIV PrEP therapy, for people ...

You can tell you're stressed. Things in life have been going a little haywire, but hey, you've been here before, no big deal. Right? Maybe someone close to you has suggested that you talk to someone, ...